Aptorum Group appoints Laura Philips to board ahead of DiamiR merger

NEW YORK - Aptorum Group Limited (NASDAQ:APM), whose stock has surged over 225% in the past six months according to InvestingPro data, announced Thursday the appointment of Dr. Laura A. Philips to its board of directors as an independent director, effective upon completion of its planned merger with DiamiR Biosciences Corp.

Dr. Philips, co-founder, President, and CEO of Spheryx, Inc., brings experience from serving on multiple life sciences company boards, including WellGen, Delcath Systems, and China Yongxin Pharmaceuticals. She previously held executive positions at NexGenix Pharmaceuticals and Corning Incorporated, and served in the Clinton Administration. The appointment comes as Aptorum maintains a healthy financial position, with InvestingPro data showing liquid assets exceeding short-term obligations and a comfortable current ratio of 2.98.

The appointment comes as part of Aptorum’s all-stock merger with DiamiR, announced on July 16, which is expected to close in the fourth quarter of 2025, subject to stockholder approval and customary closing conditions.

Following the merger, DiamiR will become a wholly-owned subsidiary of Aptorum. Dr. Kira Sheinerman, DiamiR’s co-founder, will join the combined company’s board, while Dr. Alidad Mireskandari, DiamiR’s CEO, will take an observer seat and serve as President and Chief Operating Officer.

Aptorum Group is a clinical stage biopharmaceutical company focused on developing therapeutics for oncology and infectious diseases. DiamiR specializes in molecular diagnostics, developing minimally invasive tests for early detection and monitoring of brain health conditions.

The information in this article is based on a company press release statement.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.